CagriSemaResearch, Evidence & Safety Profile

CagriSema is an investigational once-weekly subcutaneous fixed-dose combination of two peptide drugs:

• Semaglutide 2.4 mg — a glucagon-like peptide-1 (GLP-1) receptor agonist already FDA-approved as Wegovy for chronic weight management and Ozempic for type 2 diabetes.
• Cagrilintide 2.4 mg — a long-acting acylated amylin analog. Cagrilintide is investigational and not yet approved as a standalone therapy.

The fixed-dose combination is designed to engage two complementary appetite-regulating pathways in a single weekly injection. Both components are peptides, distinguishing CagriSema from oral small-molecule incretin drugs such as orforglipron (Foundayo).

CagriSema is being developed by Novo Nordisk under the REDEFINE Phase 3 program. REDEFINE-1 (in adults with obesity without diabetes) and REDEFINE-2 (in adults with obesity and type 2 diabetes) were published in the New England Journal of Medicine in 2025. REDEFINE-3, a cardiovascular outcomes trial, is ongoing. Novo Nordisk has publicly indicated it expected to submit the first regulatory filing for CagriSema in Q1 2026 based on company communications.

Regulatory caution: CagriSema has not been approved by the FDA, EMA, or any other regulatory authority. It is not commercially available outside of clinical trial enrollment. Any vendor offering "CagriSema" prior to approval is operating outside the legal framework, and the chemical identity, purity, and sterility of any such product cannot be assumed.

CagriSema's pharmacologic effects arise from simultaneous activation of two distinct appetite-regulating receptor pathways:

• GLP-1 receptor agonism (semaglutide component): Semaglutide binds the GLP-1 receptor on pancreatic beta cells, hypothalamic and brainstem appetite centers, and gastric tissue. The downstream effects are well characterized: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central satiety signaling that reduces appetite and food intake.
• Amylin and calcitonin receptor agonism (cagrilintide component): Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells. Its physiologic actions include suppressing postprandial glucagon, slowing gastric emptying, and — most relevant to weight management — activating amylin and calcitonin receptors in the area postrema and other hindbrain nuclei to promote satiety. Cagrilintide is a long-acting acylated amylin analog engineered for once-weekly dosing.

The mechanistic rationale for combining the two is that GLP-1 and amylin act on partially distinct central satiety circuits. Pre-clinical and Phase 2 data suggested that combining the two produces additive — not redundant — effects on appetite suppression and food-intake reduction at comparable doses. The REDEFINE-1 trial design included a within-trial comparison of the combination versus each component alone, providing a rare opportunity to dissect the individual and combined contributions of the two mechanisms.

The following findings are from controlled clinical trials. Results may not be representative of unstructured use, and individual response varies.

REDEFINE-1 — Obesity Without Diabetes (NEJM 2025)

REDEFINE-1 was a 68-week, Phase 3a, double-blind, placebo-controlled trial in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related complication and without diabetes. 3,417 participants were randomized to CagriSema 2.4 mg / 2.4 mg (n=2,108), semaglutide 2.4 mg alone (n=302), cagrilintide 2.4 mg alone (n=302), or placebo (n=705). The primary outcome was percent change in body weight at week 68.

• Estimated mean weight change: −20.4% with CagriSema vs −3.0% with placebo (treatment difference −17.3 percentage points, P<0.001).
• Treatment arms substantially outperformed placebo on categorical 5%, 10%, 15%, 20%, 25%, and 30% weight-loss thresholds.
• The within-trial comparison of CagriSema versus semaglutide alone or cagrilintide alone supported the additive contribution of the two mechanisms.

REDEFINE-2 — Obesity With Type 2 Diabetes (NEJM 2025)

REDEFINE-2 was a 68-week, Phase 3a, double-blind, placebo-controlled trial conducted in 12 countries in adults with BMI ≥27, HbA1c 7–10%, and type 2 diabetes. Participants were randomized 3:1 to CagriSema 2.4 mg / 2.4 mg or placebo, all with lifestyle intervention.

• Estimated mean weight loss: −13.7% with CagriSema vs approximately −3.4% with placebo.
• Substantial improvements in HbA1c and continuous-glucose-monitoring time-in-range metrics.
• Magnitude of weight loss was smaller than in REDEFINE-1 — a pattern consistent with other GLP-1 class drugs in type 2 diabetes populations.

REDEFINE-3 — Cardiovascular Outcomes

REDEFINE-3 is a cardiovascular outcomes trial in adults with overweight/obesity and established cardiovascular disease, designed to assess major adverse cardiovascular events (MACE) reduction. Results were not yet published at the time of this profile.

Comparison Context (Indirect)

No head-to-head randomized trial has compared CagriSema to other obesity pharmacotherapies. Indirect cross-trial comparisons — acknowledging different populations, durations, and analytic methods — show:

• Semaglutide 2.4 mg (STEP-1): ~14.9% mean weight loss at 68 weeks.
• Tirzepatide 15 mg (SURMOUNT-1): ~20.9% mean weight loss at 72 weeks.
• CagriSema (REDEFINE-1): ~20.4% mean weight loss at 68 weeks.

CagriSema appears to offer meaningfully greater weight loss than semaglutide monotherapy and weight loss broadly comparable to tirzepatide 15 mg. Any direct conclusion would require a head-to-head RCT, which has not been published.

The CagriSema adverse-event profile is consistent with the GLP-1 class plus the additive contribution of cagrilintide's amylin pharmacology. Gastrointestinal events were the most common reason for discontinuation in the REDEFINE program.

Common Adverse Events (REDEFINE-1)

• Gastrointestinal events were reported by approximately 79.6% of CagriSema participants vs 39.9% of placebo participants.
• Most frequent: nausea, vomiting, diarrhea, constipation, and abdominal pain.
• Most GI events were transient and mild-to-moderate in severity.
• Injection-site reactions were reported at low rates consistent with other subcutaneous peptide therapies.

Class-Level Considerations

CagriSema is anticipated to carry the GLP-1 class boxed warning for thyroid C-cell tumors based on rodent carcinogenicity findings. Class-level risks noted in the GLP-1 RA labels include pancreatitis, cholelithiasis (gallstone disease), acute kidney injury (typically secondary to dehydration from gastrointestinal adverse events), and the potential for hypoglycemia when used concurrently with insulin or sulfonylureas. The amylin component is not associated with novel safety signals in the primary REDEFINE publications.

Anticipated Contraindications

Based on class labeling for GLP-1 receptor agonists, anticipated contraindications include:

• Personal or family history of medullary thyroid carcinoma (MTC).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Known hypersensitivity to semaglutide, cagrilintide, or any excipient.

Final FDA-labeled contraindications and warnings will be established when the regulatory review is complete. Until then, contraindication and safety information should be drawn from the published trial reports.

The dosing schedule used in the REDEFINE Phase 3 trials is provided here for educational reference only. CagriSema is investigational and is not commercially available; any future FDA-labeled dosing will be defined by the prescribing information at the time of approval.

• REDEFINE-1 / REDEFINE-2 maintenance dose: Semaglutide 2.4 mg + cagrilintide 2.4 mg, once weekly, subcutaneous injection.
• Titration: Trial protocols included gradual dose escalation from a low starting dose to the 2.4 / 2.4 mg maintenance dose over multiple weeks, designed to manage gastrointestinal tolerability.
• Administration: Once weekly subcutaneous injection at any time of day, with or without food.

This information is for educational reference only. CagriSema is not FDA-approved and is not commercially available. PeptideWise does not provide dose recommendations and does not endorse use of investigational compounds outside of properly conducted clinical trial protocols.

The published evidence base for CagriSema as of April 2026 is dominated by the Novo Nordisk REDEFINE program. The two pivotal Phase 3a publications in the New England Journal of Medicine (Garvey et al., REDEFINE-1; Davies et al., REDEFINE-2) provide the primary efficacy and safety dataset. A Phase 2 study by Frias et al. in The Lancet (2023) established the proof-of-concept for the co-administered 2.4 mg / 2.4 mg regimen in adults with type 2 diabetes and informed Phase 3 dose selection.

Independent published analyses include a systematic review and meta-analysis (PMCID: PMC11642503) covering cagrilintide alone and in combination with semaglutide, and a comparative meta-analysis (PMID: 41834765) versus semaglutide monotherapy. A REDEFINE-1 secondary analysis (PMCID: PMC12822771) reported significant blood-pressure reductions consistent with the weight-loss magnitude.

The major outstanding evidence gap is the cardiovascular outcomes trial (REDEFINE-3), which had not yet reported results at the time of this profile. Until those data are available, the cardiovascular benefit of CagriSema cannot be directly established — readers should compare this with semaglutide, which has positive CV outcomes data from the SELECT trial.

No head-to-head randomized trial has been published comparing CagriSema to tirzepatide or to other approved obesity pharmacotherapies. Any direct efficacy or safety conclusion across drug classes therefore relies on indirect cross-trial comparison, which carries methodological caveats.

As of April 2026, CagriSema is investigational and has not been approved by any regulatory authority. Key facts:

• U.S. Food and Drug Administration: not approved. Novo Nordisk has indicated it expected to submit the first regulatory filing in Q1 2026 based on REDEFINE-1 and REDEFINE-2 results.
• European Medicines Agency: not approved. Filing timeline depends on Novo Nordisk's regulatory strategy.
• Other major regulators (UK MHRA, Health Canada, Japan PMDA): not approved.

Compounding pharmacies cannot legally compound CagriSema because it has not been FDA-approved and is therefore not eligible for compounding under the 503A pathway. Any vendor or telehealth service offering "CagriSema" prior to FDA approval is operating outside the legal framework.

The cagrilintide component is also being studied as standalone monotherapy. If approved, cagrilintide alone would represent the first amylin-class drug in a generation beyond pramlintide.